| Study or author |
Phase |
Line |
Target and eligibiity |
N |
Chemotherapy |
OS |
PFS |
ORR |
DCR |
| ToGA |
III |
1st |
HER2 positive |
584 |
FC |
11 |
5.5 |
34.5 |
70 |
| (ref. 9) |
|
|
(IHC3 or FISH+) |
|
FC+Trastuzumab |
13.8 |
6.7 |
47.3 |
79 |
| |
|
|
|
|
|
HR 0.71, p=0.0046 |
HR 0.71,p=0.0002 |
p=0.0017 |
|
| |
|
|
HER2 positive |
446 |
FC |
11.8 |
|
|
|
| |
|
|
(IHC3+ or IHC2+/FISH+) |
|
FC+Trastuzumab |
16 |
|
|
|
| |
|
|
|
|
HR 0.65 |
|
|
|
| REAL-3 |
III |
1st |
EGFR
Not defined |
553 |
EOC |
11.3 |
7.4 |
42 |
63 |
| (ref.27) |
|
|
|
EOC+Panitumumab |
8.8 |
6 |
46 |
64 |
| |
|
|
|
|
|
HR 1.37, p=0.013 |
HR 1.22, p=0.068 |
P=0.467 |
|
| Kim et al |
II |
2nd |
EGFR
Not defined |
77 |
Irinotecan+nimotuzumab |
227 days |
85 days |
10.3 |
46.2 |
| (ref. 28) |
|
|
|
Irinotecan |
293 days |
73 days |
18.4 |
47.3 |
| |
|
|
|
|
|
HR 0.717, p=0.22 |
HR 0.86 ,p=0.5668 |
|
|
| AVAGAST |
III |
1st |
VEGF
Not defined |
774 |
XP |
10.1 |
5.3 |
37 |
66.7 |
| (ref. 29) |
|
|
|
XP+Bevacizumab |
12.1 |
6.7 |
46 |
75.9 |
| |
|
|
|
|
|
HR=0.87,p=0.1002 |
HR=0.80,p=0.0037 |
p=0.0315 |
|
| GRANITE-1 |
III |
2nd/3rd |
mTOR
Not defined |
656 |
Placebo |
4.34 |
1.41 |
2.1 |
22 |
| (ref.42) |
|
|
|
Everolimus |
5.39 |
1.68 |
4.5 |
43.3 |
| |
|
|
|
|
|
HR 0.90,p=0.1244 |
HR 0.66, p<.0001 |
|
|
| Ivenson, et al. |
II |
1st |
HGF
Not defined |
121 |
ECX |
8.9 |
4.2 |
21 |
76 |
| (ref.46) |
|
|
|
ECX+rilotumumab |
11.1 |
5.6 |
38 |
80 |
| |
|
|
|
|
|
HR=0.73,p=0.215 |
HR=0.64,p=0.045 |
p=0.089 |
|
| |
|
|
High c-Met |
38* |
ECX |
5.7 |
4.6 |
|
|
| |
|
|
(>50% of cell, exploratory analysis) |
|
ECX+rilotumumab |
11.1 |
6.9 |
|
|
| |
|
|
|
|
HR=0.29 |
HR=0.53 |
|
|
* Among 90 evaluable patients
Abbraviations; OS, overall survival; PFS, progression-free survival: ORR, overall response rate; DCR, disease control rate: HR, hazard ratio; FC, Capecitabine/5-
FU+Cisplatin; XP, Capecitabine+Cisplatin; EOC, Epirubicin+Oxaliplatin+Capecitabine; ECX, Epirubicin+Cisplatin+Capecitabine |
